Recombinant Human CHRNb4 protein

The CHRNB4 recombinant protein is derived from the β4 subunit of the neuronal nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel critical for synaptic signaling in the nervous system. nAChRs are pentameric complexes composed of α and β subunits, with the β4 subunit (encoded by the CHRNB4 gene) playing a key role in forming functional receptors, particularly when paired with α3 subunits (α3β4 receptors). These receptors are predominantly expressed in the autonomic ganglia, adrenal medulla, and specific brain regions, influencing neurotransmitter release, synaptic plasticity, and behaviors related to addiction and reward.

Recombinant CHRNB4 protein is engineered using expression systems like Escherichia coli or mammalian cells to produce purified, functional subunits for structural and functional studies. Its production enables detailed investigation into receptor assembly, ligand binding (e.g., nicotine or acetylcholine), and ion channel gating mechanisms. Researchers utilize this protein to explore its role in neurological and psychiatric disorders, including nicotine dependence, epilepsy, and neuropathic pain. Additionally, it serves as a tool for drug discovery, aiding in the development of therapeutics targeting nAChRs. Studies on CHRNB4 variants also provide insights into genetic factors influencing receptor function and disease susceptibility. Overall, CHRNB4 recombinant protein is pivotal for advancing understanding of cholinergic signaling and its implications in health and disease.